NASDAQ: OCS

Oculis Holding Ag Stock Forecast, Predictions & Price Target

The consensus among 4 Wall Street analysts covering (NASDAQ: OCS) stock is to Strong Buy OCS stock.

Out of 4 analysts, 1 (25%) are recommending OCS as a Strong Buy, 3 (75%) are recommending OCS as a Buy, 0 (0%) are recommending OCS as a Hold, 0 (0%) are recommending OCS as a Sell, and 0 (0%) are recommending OCS as a Strong Sell.

If you're new to stock investing, here's how to buy Oculis Holding Ag stock.

(NASDAQ: OCS) Oculis Holding Ag's forecast annual revenue growth rate of 203.88% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.35%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.76%.

Oculis Holding Ag's revenue in 2024 is $962,637.On average, 4 Wall Street analysts forecast OCS's revenue for 2024 to be $37,181,179, with the lowest OCS revenue forecast at $33,066,266, and the highest OCS revenue forecast at $41,149,130. On average, 3 Wall Street analysts forecast OCS's revenue for 2025 to be $695,236,602, with the lowest OCS revenue forecast at $65,397,725, and the highest OCS revenue forecast at $1,735,611,536.

In 2026, OCS is forecast to generate $916,523,399 in revenue, with the lowest revenue forecast at $687,410,919 and the highest revenue forecast at $1,109,924,312.

According to 4 Wall Street analysts that have issued a 1 year OCS price target, the average OCS price target is $30.50, with the highest OCS stock price forecast at $35.00 and the lowest OCS stock price forecast at $28.00.

On average, Wall Street analysts predict that Oculis Holding Ag's share price could reach $30.50 by Apr 24, 2025. The average Oculis Holding Ag stock price prediction forecasts a potential upside of 152.69% from the current OCS share price of $12.07.

(NASDAQ: OCS) forecast ROE is N/A, which is considered weak.